Biosimilars Drive Significant Reductions in Specialty Drug Spending
Decision brief
Answer first · skim in under a minute
Biosimilars are poised to significantly reduce specialty drug expenditures, with projections indicating potential savings of up to 20%. This analysis explores the market impact, patient cost benefits, and strategic implications for the pharmaceutical industry.
Biosimilars are now a measurable brake on U.S. specialty biologic spend. Federal analysts estimate billions in Medicare Part B savings, while peer-reviewed work shows originator average sales prices falling for years after the first competitor launches.
Contents9 sections
Key Takeaways
- ASPE estimates $12.9 billion in Medicare Part B spending reductions from biosimilar competition in 2018–2023, including $4.4 billion in 2023.
- Those cuts equal about 31% less spending than a no-competition projection for the studied biologics over 2018–2023, and about 62% in 2023 alone.
- ASPE also estimates $3.2 billion lower beneficiary out-of-pocket costs over 2018–2023, about $2,000 average annual potential OOP savings per affected beneficiary in 2023 before supplemental coverage.
- JAMA Network Open modeling found originator ASP declines near 43.1% by five years after biosimilar entry.
What does HHS ASPE say about Medicare Part B savings?
The HHS Assistant Secretary for Planning and Evaluation report on Medicare Part B enrollee use and spending on biosimilars, 2018–2023 estimates $12.9 billion in reduced Part B drug spending versus a counterfactual without biosimilar entry. The 2023 slice alone is $4.4 billion.
ASPE frames those figures as 31% savings over 2018–2023 and 62% savings in 2023 relative to projected spend without competition for the studied products. Product-group savings in 2023 ranged from about 44% to 81% for most groupings in the report’s summary tables.
How do originator prices move after biosimilar launch?
A JAMA Network Open cohort analysis (PMC full text) of Medicare Part B average sales prices found originator biologic ASP changes of about −7.4% at one year, −31.7% at three years, and −43.1% at five years after biosimilar entry. Biosimilar ASPs were generally lower than the reference products across post-entry periods.
Price cuts alone do not guarantee system savings. Uptake volume still decides whether payers capture the list-price gap. ASPE and academic authors both stress adoption barriers as the remaining bottleneck.
What is the FDA biosimilar standard?
FDA’s biosimilar pathway requires that a product be highly similar to a reference biologic and that there be no clinically meaningful differences in safety, purity, and potency for approved uses. Sponsors and payers should start from FDA biosimilars materials when educating clinicians, not from marketing slogans.
- Part B savings 2018–2023: $12.9 billion (ASPE)
- Part B savings 2023: $4.4 billion (ASPE)
- Beneficiary OOP reduction 2018–2023: $3.2 billion (ASPE)
- Originator ASP change at 5 years: about −43.1% (JAMA Network Open)
What should pharmacy and market-access teams do?
Track ASP files, interchangeability designations, and medical-benefit switching policies separately from pharmacy-benefit generics habits. Specialty spend lives on the medical benefit for many Part B products. Contracting and buy-and-bill incentives can dominate list-price comparisons.
Build dashboards that show both biosimilar share and originator ASP decline for each molecule. A market with high biosimilar share but sticky originator ASP still leaves money on the table. A market with falling originator ASP but low biosimilar share may still save money through reference-price pressure alone. ASPE’s 31% and 62% savings figures show how large that combined effect can be once competition bites.
For employer and Medicare Advantage teams, translate ASPE’s roughly $2,000 average potential annual out-of-pocket figure carefully. Supplemental coverage can mute coinsurance. Still, the direction is clear: biosimilar competition lowers the Part B coinsurance base for many specialty infusions.
What remains unproven?
ASPE savings are model-based against a no-biosimilar counterfactual. They are not audited cash recoveries for every plan. JAMA Network Open estimates describe ASP trajectories for a limited set of originators and do not measure net plan spend after rebates. Do not extrapolate a single product’s discount to the entire specialty category. Also do not assume pharmacy-benefit interchangeability rules automatically transfer to physician-administered Part B products without policy work.
Related NovaPharma coverage
Frequently Asked Questions
How much did biosimilars save Medicare Part B?
HHS ASPE estimates biosimilar competition reduced Medicare Part B drug spending by $12.9 billion between 2018 and 2023, including $4.4 billion in 2023, versus a no-biosimilar counterfactual.
Do originator biologic prices fall after biosimilar entry?
A JAMA Network Open cohort study estimated average sales price reductions for originator biologics of about 7.4% at one year, 31.7% at three years, and 43.1% at five years after biosimilar entry.
Are biosimilars FDA-reviewed for similarity?
Yes. FDA approves biosimilars under a pathway that requires no clinically meaningful differences from the reference product in safety, purity, and potency for the approved conditions of use.
Primary Sources
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
